0 CHECKOUT

Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2015

  • ID: 3293079
  • May 2015
  • 175 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • Assessment by Target
  • Forward Pharma A/S
  • Mapi Pharma Ltd.
  • Novartis AG
  • RedHill Biopharma Ltd.
  • MORE

Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2015

Summary

This, ‘Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2015’, provides an overview of the Relapsing Remitting Multiple Sclerosis (RRMS)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • Assessment by Target
  • Forward Pharma A/S
  • Mapi Pharma Ltd.
  • Novartis AG
  • RedHill Biopharma Ltd.
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Relapsing Remitting Multiple Sclerosis (RRMS) Overview
Therapeutics Development
Pipeline Products for Relapsing Remitting Multiple Sclerosis (RRMS) - Overview
Pipeline Products for Relapsing Remitting Multiple Sclerosis (RRMS) - Comparative Analysis
Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics under Development by Companies
Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics under Investigation by Universities/Institutes
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Relapsing Remitting Multiple Sclerosis (RRMS) - Products under Development by Companies
Relapsing Remitting Multiple Sclerosis (RRMS) - Products under Investigation by Universities/Institutes
Relapsing Remitting Multiple Sclerosis (RRMS) - Companies Involved in Therapeutics Development
AbbVie Inc.
Actelion Ltd
Allozyne, Inc.
Amarna Therapeutics B.V.
Antisense Therapeutics Limited
Biogen, Inc.
Cognosci, Inc.
F. Hoffmann-La Roche Ltd.
Forward Pharma A/S
Genmab A/S
GlaxoSmithKline plc
Iltoo Pharma
Mapi Pharma Ltd.
MedImmune, LLC
Merck KGaA
Mitsubishi Tanabe Pharma Corporation
Neurotec Pharma SL
Novartis AG
Nuron Biotech, Inc.
Octapharma AG
Opexa Therapeutics, Inc.
RedHill Biopharma Ltd.
Sanofi
Synthetic Biologics, Inc.
Teva Pharmaceutical Industries Limited
XenoPort, Inc.
Zydus Cadila Healthcare Limited
Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(rifabutin + clarithromycin + clofazimine) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
aldesleukin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ATL-1102 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ATXMS-1467 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AZ-17 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy for Relapsing Remitting Multiple Sclerosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
COG-133 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
daclizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diazoxide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dimethyl fumarate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
estriol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy for Relapsing and Remitting Multiple Sclerosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
glatiramer acetate ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK-239512 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Guanabenz - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HR-411 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
hydralazine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
imilecleucel-t - Drug Profile
Product Description
Mechanism of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
interferon beta-1b - Drug Profile
Product Description
Mechanism of Action
R&D Progress
interferon beta-1b - Drug Profile
Product Description
Mechanism of Action
R&D Progress
interferon beta-1b - Drug Profile
Product Description
Mechanism of Action
R&D Progress
laquinimod sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MEDI-551 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MT-1303 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ofatumumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
olesoxime - Drug Profile
Product Description
Mechanism of Action
R&D Progress
opicinumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pegylated Interferon-Beta-1b - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ponesimod - Drug Profile
Product Description
Mechanism of Action
R&D Progress
siponimod - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Target CTLA4 and IFNGR for RRMS - Drug Profile
Product Description
Mechanism of Action
R&D Progress
vatelizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VAY-736 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
XP-23829 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Relapsing Remitting Multiple Sclerosis (RRMS) - Recent Pipeline Updates
Relapsing Remitting Multiple Sclerosis (RRMS) - Dormant Projects
Relapsing Remitting Multiple Sclerosis (RRMS) - Discontinued Products
Relapsing Remitting Multiple Sclerosis (RRMS) - Product Development Milestones
Featured News & Press Releases
Feb 26, 2015: Abbvie's Ongoing Research In Neuroscience And Oncology On ZINBRYTA Will Be Featured At The 2015 American Academy Of Neurology Annual Meeting
Dec 17, 2014: First Patient Treated in Mapi Pharma's Phase IIa Clinical Trial of GA Depot for Relapsing Remitting Multiple Sclerosis
Nov 04, 2014: Genzyme Announces Enrollment of First Patient in Phase II Vatelizumab Trial in Relapsing Remitting Multiple Sclerosis
Sep 12, 2014: Detailed Results from Biogen Idec and AbbVie’s Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA (Daclizumab High-Yield Process)
Sep 12, 2014: Teva Presents New Clinical Safety Data in RRMS Patients Treated with Laquinimod for Two or More Years at Joint ACTRIMS-ECTRIMS Meeting
Jul 31, 2014: Expanded Data on Disability and Cognitive Improvements in Phase II Study of Synthetic Biologics' Trimesta in Multiple Sclerosis to be Presented at 2014 Joint ACTRIMS-ECTRIMS Meeting
May 30, 2014: Genmab Announces Ofatumumab Development Plans in RRMS and NMO
May 23, 2014: Teva and Active Biotech to Continue with the Development of Nerventra for Multiple Sclerosis Following Confirmation of CHMP Opinion
Apr 29, 2014: Synthetic Biologics Reports University of California, Los Angeles Announcement Of Preliminary Positive Topline Efficacy And Safety Results From Investigator-Led Phase 2 Study Of Trimesta For Relapsing-Remitting Multiple Sclerosis
Apr 07, 2014: ATL1102 for MS - US Patent Allowance Extends Strong IP Position
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Relapsing Remitting Multiple Sclerosis (RRMS), H1 2015
Number of Products under Development for Relapsing Remitting Multiple Sclerosis (RRMS) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by AbbVie Inc., H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Actelion Ltd, H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Allozyne, Inc., H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Amarna Therapeutics B.V., H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Antisense Therapeutics Limited, H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Biogen, Inc., H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Cognosci, Inc., H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Forward Pharma A/S, H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Genmab A/S, H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by GlaxoSmithKline plc, H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Iltoo Pharma, H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Mapi Pharma Ltd., H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by MedImmune, LLC, H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Merck KGaA, H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Neurotec Pharma SL, H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Novartis AG, H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Nuron Biotech, Inc., H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Octapharma AG, H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Opexa Therapeutics, Inc., H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by RedHill Biopharma Ltd., H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Sanofi, H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Synthetic Biologics, Inc., H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by XenoPort, Inc., H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Zydus Cadila Healthcare Limited, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics - Recent Pipeline Updates, H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Dormant Projects, H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Dormant Projects (Contd..1), H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Dormant Projects (Contd..2), H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Discontinued Products, H1 2015
Relapsing Remitting Multiple Sclerosis (RRMS) - Discontinued Products (Contd..1), H1 2015

List of Figures
Number of Products under Development for Relapsing Remitting Multiple Sclerosis (RRMS), H1 2015
Number of Products under Development for Relapsing Remitting Multiple Sclerosis (RRMS) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

AbbVie Inc.
Actelion Ltd
Allozyne, Inc.
Amarna Therapeutics B.V.
Antisense Therapeutics Limited
Biogen, Inc.
Cognosci, Inc.
F. Hoffmann-La Roche Ltd.
Forward Pharma A/S
Genmab A/S
GlaxoSmithKline plc
Iltoo Pharma
Mapi Pharma Ltd.
MedImmune, LLC
Merck KGaA
Mitsubishi Tanabe Pharma Corporation
Neurotec Pharma SL
Novartis AG
Nuron Biotech, Inc.
Octapharma AG
Opexa Therapeutics, Inc.
RedHill Biopharma Ltd.
Sanofi
Synthetic Biologics, Inc.
Teva Pharmaceutical Industries Limited
XenoPort, Inc.
Zydus Cadila Healthcare Limited
lapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics Asses
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Shire PLC.
  • GlaxoSmithKline PLC
  • Astrazeneca PLC
  • Roche Diagnostics Ltd.
  • H. Lundbeck A/S
  • Electrical Geodesics, Inc.